Semorex Technologies

Company Overview

Snapshot

Founded in March 2002, Semorex Technologies operates with 1–10 employees. The company has secured grants across two funding rounds. In December 2015, it received a grant from Israel's Agency for International Development Cooperation and Office of the Chief Scientist.

Business overview

Semorex Technologies is a Health Tech & Life Sciences company focused on developing cancer therapeutics and diagnostics for fungal infections. The company has discovered molecular compounds with potent and selective anticancer activity against solid tumors and hematological malignancies, which have shown to be nontoxic in mice models. Additionally, Semorex has developed a diagnostic approach for the rapid and reliable diagnosis of systemic/invasive fungal infection (SFI/IFI), aiming to provide quick and appropriate treatment for patients.

Company Intelligence Q&A

What is Semorex Technologies' primary focus?

Semorex Technologies focuses on discovering molecular compounds for cancer therapeutics and developing diagnostic approaches for systemic/invasive fungal infections (SFI/IFI).

When was Semorex Technologies founded?

Semorex Technologies was founded in March 2002.

What type of funding has Semorex Technologies received?

Semorex Technologies has received non-equity funding in the form of grants. The company secured grants in March 2015 and December 2015, with the Office of the Chief Scientist participating in both rounds, and Israel's Agency for International Development Cooperation joining the December 2015 round.

Which entities provided a grant to Semorex Technologies in December 2015?

In December 2015, Semorex Technologies received a grant from Israel's Agency for International Development Cooperation and Office of the Chief Scientist.

What is the status of Semorex Technologies?

Semorex Technologies is Non Active, having ceased to operate in January 2019.